Poslední aktualizace :
08/05/2024
Antibiotikum   Netilmicin sulfate  
Injekce
Aerosol
Stabilita roztoků Stabilita směsí Faktory ovlivňující stabilitu Kompatibilita Způsoby aplikace Odkazy Pdf
   Chemický vzorec  

Obchodní název   Obchodní název     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bactob Indie
Beltob Indie
Bramicil Itálie
Brulamycin MaÔarsko
Eltol Indie
Fytobra Indie
Gernebcin NÏmecko
Komitub Indie
Nebcin Austrálie, Egypt, Nový Zéland, Saúdská Arábie, Spojené arabské emiráty, Velká Británie, ÿecko
Nebcina Dánsko, Maroko, Norsko, Švédsko
Nebcine Maroko
Nebicina Itálie
Netilyn Finsko, Švédsko
Netromicina Portugalsko
Netromicine Francie
Netromycine Polsko, Rusky, Turecko, ÿecko
Nettacin Itálie
Obracin Belgie, Lucembursko, Nizozemsko, Švýcarsko
Tobra NÏmecko
Tobra Alex Egypt
Tobra Day Nový Zéland
Tobra Gobens äpanÏlsko
Tobracin Egypt
Tobradistin äpanÏlsko
Tobramicina äpanÏlsko, Itálie, Portugalsko, Venezuela
Tobramina BrazÌlie
Tobramycin Austrálie, Irsko, Kanada, NÏmecko, Norsko, Saúdská Arábie, USA, Velká Británie
Tobramycine Belgie, Kanada, Lucembursko, Nizozemsko
Tobrasix Rakousko
Tobrazid NÏmecko
Tomycin Finsko
Zetamicin Itálie
Odkazy   Injekce   Odkazy : Netilmicin sulfate  
Typ Uveřejnění
3 Noviny Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 Noviny Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
84 Noviny Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Noviny Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Noviny Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Noviny Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Noviny Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
289 Noviny Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707.
299 Noviny Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Noviny Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Noviny Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
335 Noviny Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
367 Noviny Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119.
421 Noviny Foley PT, Bosso JA, Bair JN, Townsend RJ.
Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures.
Am J Hosp Pharm 1985 ; 42: 839-843.
492 Noviny Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 Noviny Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Noviny Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
958 Noviny Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M.
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion.
Ann Pharmacotherapy 1990 ; 24: 440-442.
999 Noviny Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1022 Noviny Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886.
1035 Noviny Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132.
1200 Noviny Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742.
1236 Noviny Kuhn RJ, Nahata MC.
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Am J Hosp Pharm 1986 ; 43: 1241-1242.
1410 Noviny Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Noviny Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Noviny Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1754 Noviny Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1925 Noviny Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1929 Noviny Rigge DC, Jones MF.
Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes.
J Pharm Biomed Anal 2004 ; 35: 1251-1256.
2296 Laboratoř Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3522 Laboratoř Flucloxacillin - Summary of Product Characteristics.
Actavis 2013
3523 Laboratoř Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3526 Laboratoř Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3527 Laboratoř Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018
3540 Laboratoř Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3543 Laboratoř Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3544 Laboratoř Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006
3545 Laboratoř Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009
3546 Laboratoř Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3548 Laboratoř Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3578 Laboratoř Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3586 Laboratoř Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010
3587 Laboratoř Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014
3594 Laboratoř Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013
3644 Laboratoř Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3656 Laboratoř Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014
3674 Laboratoř Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3687 Laboratoř Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013
3883 Laboratoř Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016

  Mentions Légales